| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin
|
Hellwig, Martin D.
|
|
|
57 |
1 |
p.
|
article
|
| 2 |
Advanced statistical methods and designs for clinical trials for COVID-19
|
Shan, Guogen
|
|
|
57 |
1 |
p.
|
article
|
| 3 |
Antimicrobial efficacy and prevalence of colicinogenic E. coli in faecal matter of human, cow and sheep
|
Mushtaq, Hira
|
|
|
57 |
1 |
p.
|
article
|
| 4 |
Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model
|
Thomsen, Kim
|
|
|
57 |
1 |
p.
|
article
|
| 5 |
Can we use hydroxychloroquine to treat COVID-19 now?
|
Chen, Jun
|
|
|
57 |
1 |
p.
|
article
|
| 6 |
Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19
|
Gautret, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 7 |
Doxycycline as an Alternative to Azithromycin in Elderly Patients
|
Malek, Alexandre Elias
|
|
|
57 |
1 |
p.
|
article
|
| 8 |
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial
|
Parra-Lara, Luis Gabriel
|
|
|
57 |
1 |
p.
|
article
|
| 9 |
Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes
|
Gautret, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 10 |
Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
|
Million, Matthieu
|
|
|
57 |
1 |
p.
|
article
|
| 11 |
Epidemiology and prevalence of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa
|
Ouchar Mahamat, Oumar
|
|
|
57 |
1 |
p.
|
article
|
| 12 |
Evaluation of area under the concentration–time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury
|
Muklewicz, Justin D.
|
|
|
57 |
1 |
p.
|
article
|
| 13 |
Focus on clinical outcomes of “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
|
Wambier, Carlos Gustavo
|
|
|
57 |
1 |
p.
|
article
|
| 14 |
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited
|
Gautret, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 15 |
Hydroxychloroquine (HCQ): real treatment or false hope?
|
El Bakkouri, Karim
|
|
|
57 |
1 |
p.
|
article
|
| 16 |
Impact of a non-compulsory antifungal stewardship program on overuse and misuse of antifungal agents in a tertiary care hospital
|
Markogiannakis, Antonios
|
|
|
57 |
1 |
p.
|
article
|
| 17 |
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
|
|
|
|
57 |
1 |
p.
|
article
|
| 18 |
Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19
|
Colson, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 19 |
Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital
|
Arcari, Gabriele
|
|
|
57 |
1 |
p.
|
article
|
| 20 |
Letter to the editor about “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”
|
Saad, Mohamed O
|
|
|
57 |
1 |
p.
|
article
|
| 21 |
Long-acting drugs and formulations for the treatment and prevention of HIV infection
|
Flexner, Charles
|
|
|
57 |
1 |
p.
|
article
|
| 22 |
Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality
|
De Schryver, Nicolas
|
|
|
57 |
1 |
p.
|
article
|
| 23 |
LPD-12: a promising lipopeptide to control COVID-19
|
Chowdhury, Trinath
|
|
|
57 |
1 |
p.
|
article
|
| 24 |
Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?
|
Freitas, Ana R.
|
|
|
57 |
1 |
p.
|
article
|
| 25 |
Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales
|
Piccirilli, Alessandra
|
|
|
57 |
1 |
p.
|
article
|
| 26 |
Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China
|
Huang, Lin
|
|
|
57 |
1 |
p.
|
article
|
| 27 |
Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies—need for data validation of the completed trials and to improve ongoing and future randomised trial designs
|
Emani, Venkata R.
|
|
|
57 |
1 |
p.
|
article
|
| 28 |
Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial
|
dos Santos, Marcelo Rodrigues
|
|
|
57 |
1 |
p.
|
article
|
| 29 |
Response to advances statistical methods and designs for clinical trials for COVID-19
|
Gautret, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 30 |
Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
|
Gautret, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 31 |
Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
|
Gautret, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 32 |
Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
|
Gautret, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 33 |
Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial
|
Li, Guoming
|
|
|
57 |
1 |
p.
|
article
|
| 34 |
Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients
|
Gautret, Philippe
|
|
|
57 |
1 |
p.
|
article
|
| 35 |
Temocillin susceptibility in Enterobacterales with an ESBL/AmpC phenotype
|
Kresken, M.
|
|
|
57 |
1 |
p.
|
article
|
| 36 |
Title Page & Editorial Board
|
|
|
|
57 |
1 |
p.
|
article
|
| 37 |
Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load
|
Nguyen, Tuan V.
|
|
|
57 |
1 |
p.
|
article
|
| 38 |
Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature
|
Goldman, Jason D.
|
|
|
57 |
1 |
p.
|
article
|
| 39 |
Using the clinical information system and self-supervision to rationalize the need for antibiotic stewardship: An interventional study in a 2000-bed university hospital
|
Viala, Benjamin
|
|
|
57 |
1 |
p.
|
article
|
| 40 |
Whole Genome Sequencing of Staphylococcus aureus SA-1199B Reveals Previously Unreported Mutations
|
Laws, Mark
|
|
|
57 |
1 |
p.
|
article
|
Journal description